Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 13, 2016Cardiovascular TherapeuticsOpen Access

Protective effects of low‐dose rosuvastatin on isoproterenol‐induced chronic heart failure in rats by regulation of DDAH‐ADMA‐NO pathway

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does low-dose rosuvastatin improve isoproterenol-induced chronic heart failure in rats?

Population

Male Sprague Dawley rats with isoproterenol-induced chronic heart failure

Comparison

Low-dose rosuvastatin orally administrated from… vs Isoproterenol-induced heart failure rats without…

Design

Preclinical

Follow-up

14 days

Authors

RZRu ZhouPMPing MaXAXiong Aiqin

Discussion

Loading...

Member takes

Overview

Rosuvastatin may protect against experimental HF in rats; leaves open clinical translation and requires human trials.

Structured PICO

Does low-dose rosuvastatin improve isoproterenol-induced chronic heart failure in rats?

P
Population
Male Sprague Dawley rats with isoproterenol-induced chronic heart failure (isoproterenol 5 mg/kg once a day for 7 days by subcutaneous injection)
I
Intervention
Low-dose rosuvastatin (5 mg/kg) orally administrated from day 1 to day 14
C
Comparator
Isoproterenol-induced heart failure rats without rosuvastatin treatment (implied control)
O
Outcome
Hemodynamic parameters, histopathological variables, serum asymmetric dimethylarginine (ADMA), cardiac troponin I (cTnI), brain natriuretic peptide (BNP), myocardial nitric oxide (NO), and expression levels of DDAH2, PRMT1, and eNOSsurrogate

Low-dose rosuvastatin exerts cardioprotective effects on isoproterenol-induced heart failure in rats by modulating the DDAH-ADMA-NO pathway.

Cite This Study

Zhou et al. (2016) studied this question.

synapsesocial.com/papers/6a1bef44c97d63156a5f1bfehttps://doi.org/10.1111/1755-5922.12241
View Full Paper
Ask AI
Bookmark
Share